A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer
Tebbutt, N.C., Norman, A., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Harper, P., Maisey, N., Mochlinski, K., Prior, Y. and Hill, M. (2002) A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Annals of Oncology, 13, (10), 1568-1575. (doi:10.1093/annonc/mdf273).
Download
Full text not available from this repository.
Description/Abstract
Background: this randomised study compared protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin C (MMC) in patients with advanced oesophago-gastric cancer.
Patients and methods: two hundred and fifty-four patients with adenocarcinoma, squamous cell carcinoma or undifferentiated carcinoma involving the oesophagus, oesophago-gastric junction or the stomach were randomised. The major end points were tumour response, survival, toxicity and quality of life.
Results: the median age of patients treated was 72 years and the two arms were well-balanced for baseline demographic factors. The overall response rate was 16.1% [95% confidence interval (CI) 9.5% to 22.7%] in patients treated with PVI 5-FU alone compared with 19.1% (95% CI 12.0% to 26.0%) for those treated with PVI 5-FU plus MMC (P = 0.555). Median time to treatment failure was 3.9 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P = 0.195). Median survival was 6.3 months for PVI 5-FU and 5.3 months for PVI 5-FU plus MMC (P = 1.0).Toxicity was mild for both treatments. Symptomatic benefit measured by improvement in pain control, weight loss, dysphagia and oesophageal reflux was observed in over 64% of patients in each arm. Quality of life scores were comparable in each arm.
Conclusions: PVI 5-FU is a safe, effective form of palliation for patients with advanced oesophago-gastric cancer although the addition of MMC adds little extra benefit.
| Item Type: | Article |
|---|---|
| ISSNs: | 0923-7534 (print) |
| Related URLs: | |
| Keywords: | 5-fluorouracil, mitomycin C, oesophago-gastric cancer |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | University Structure - Pre August 2011 > School of Medicine > Cancer Sciences |
| Item ID: | 26634 |
| Date Deposited: | 21 Apr 2006 |
| Last Modified: | 01 Jun 2011 06:29 |
| Contributors: | Tebbutt, N.C. (Author) Norman, A. (Author) Cunningham, D. (Author) Iveson, T. (Author) Seymour, M. (Author) Hickish, T. (Author) Harper, P. (Author) Maisey, N. (Author) Mochlinski, K. (Author) Prior, Y. (Author) Hill, M. (Author) |
| Date: | 2002 |
| Status: | Published |
| URI: | http://eprints.soton.ac.uk/id/eprint/26634 |
Actions (login required)
 |
View Item |
